A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection
Open Access
- 15 February 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 31 (2) , 81-90
Abstract
The development of a universal influenza vaccine that can provide a robust and long-lasting protection against a broader range of influenza virus strains is a global public health priority. One approach to improve vaccine efficacy is to use an adjuvant to boost immune responses to the target antigens; nevertheless, the role of adjuvants in the context of influenza vaccines is not fully understood. We have previously developed the K3-schizophyllan (SPG) adjuvant, which is composed of nanoparticulated oligodeoxynucleotides K3, a TLR9 agonist, with SPG, a non-agonistic β-glucan ligand of Dectin-1. In this study, K3-SPG given with conventional influenza hemagglutinin (HA) split vaccine (K3-SPG HA) conferred protection against antigenically mismatched heterologous virus challenge. While K3-SPG HA elicited robust cross-reactive HA-specific IgG2c and CD8 T-cell responses, CD8 T-cell depletion had no impact on this cross-protection. In contrast, K3-SPG HA was not able to confer protection against heterologous virus challenge in FcRγ-deficient mice. Our results indicated that FcγR-mediated antibody responses induced by the HA antigen and K3-SPG adjuvant were important for potent protection against antigenically mismatched influenza virus infection. Thus, we demonstrated that the K3-SPG-adjuvanted vaccine strategy broadens protective immunity against influenza and provides a basis for the development of next-generation influenza vaccines.Keywords
Funding Information
- National Institutes of Biomedical Innovation, Health and Nutrition
- Japan Agency for Science and Technology (JST) CREST (JPMJCR18H1)
- Japan Society for the Promotion of Science (JP17H05087)
- Agency for Medical Research and Development (JP17ak0101068, JP17fk0108124, JP17fk0108207)
- National Institutes of Health
This publication has 45 references indexed in Scilit:
- Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer ProtectionCell Host & Microbe, 2016
- Influenza Vaccine Effectiveness: Mysteries, Enigmas, and a Few CluesThe Journal of Infectious Diseases, 2016
- Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunityExpert Review of Vaccines, 2015
- Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza VaccineThe Journal of Immunology, 2014
- Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivoNature Medicine, 2014
- Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic AntibodiesFrontiers in Immunology, 2013
- Highly Conserved Protective Epitopes on Influenza B VirusesScience, 2012
- Catching a Moving TargetScience, 2011
- MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza VaccinesScience Translational Medicine, 2011
- Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variationNature, 1981